Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 47

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 47
---
 skilled employees, which we believe would put us at a significant competitive disadvantage in our industry and
would not be in our stockholders’ best interests, as it would remove incentives aligning the interests of our employees and our senior leaders with those of our stockholders to drive company-wide performance and create long-term stockholder
value, and would reduce the amount of cash that we have available to dedicate to our other business needs. Given that equity awards, and in particular stock options, are a critical part of the compensation at pharmaceutical companies of our stage,
the inability to grant equity awards under the 2021 Plan would put us in significant jeopardy of losing key employees and executive officers, and would make it much more difficult for us to retain employees and executive officers, all of which would
be detrimental to the interests of Aadi and its stockholders.

Risk Factors Related to the Divestiture, the PIPE Financing, the License Agreement and the ADC Programs(see page [●])

In evaluating the proposals described herein, you should carefully read this proxy statement and especially
consider the factors discussed in the section entitled “Risk Factors”, beginning on page [●].

- 31 -

Risks Related to the Pending Divestiture

| • |     | The pendency of the Divestiture could have an adverse effect on our business and results of operations, and the                                                   
 failure to complete the Divestiture in a timely manner or at all could adversely affect our business, financial condition, results of operations and stock price. |

| • |     | The Divestiture is subject to conditions, some or all of which may not be satisfied, or completed on a timely                                                                                                                                     
 basis, if at all. There can be no guarantees that the Divestiture will be completed. Failure to complete, or unexpected delays in completing, the Divestiture or any termination of the Divestiture Agreement could have an adverse effect on our 
 financial condition and results of operations.                                                                                                                                                                                                    |

| • |     | While the Divestiture is pending, we are subject to business uncertainties and contractual restrictions that 
 could harm our business relationships, financial condition, results of operations, and business.             |

| • |     | The announcement and pendency of the Divestiture, whether or not consummated, may adversely affect our business 
 and operations.                                                                                                 |

| • |     | The Divestiture Agreement contains provisions that limit our ability to pursue alternatives to the Divestiture,                                                                                                      
 which could discourage a third party from making a